171 reports of this reaction
4.0% of all DIHYDROERGOTAMINE MESYLATE reports
#8 most reported adverse reaction
NEPHROLITHIASIS is the #8 most commonly reported adverse reaction for DIHYDROERGOTAMINE MESYLATE, manufactured by Impel Pharmaceuticals LLC. There are 171 FDA adverse event reports linking DIHYDROERGOTAMINE MESYLATE to NEPHROLITHIASIS. This represents approximately 4.0% of all 4,245 adverse event reports for this drug.
Patients taking DIHYDROERGOTAMINE MESYLATE who experience nephrolithiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROLITHIASIS is moderately reported among DIHYDROERGOTAMINE MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to nephrolithiasis, the following adverse reactions have been reported for DIHYDROERGOTAMINE MESYLATE:
The following drugs have also been linked to nephrolithiasis in FDA adverse event reports:
NEPHROLITHIASIS has been reported as an adverse event in 171 FDA reports for DIHYDROERGOTAMINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROLITHIASIS accounts for approximately 4.0% of all adverse event reports for DIHYDROERGOTAMINE MESYLATE, making it a notable side effect.
If you experience nephrolithiasis while taking DIHYDROERGOTAMINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.